ALTSA: NH #2021-002

ALTSA: NH #2021-002

Recently, the Centers for Disease Control and Prevention (CDC) issued updated “Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States.” The information is located here:  Under the section titled “Laboratory Reporting,” the CDC provided recommendations about the timing of the administration of the mRNA COVID-19 vaccine and Tuberculosis (TB) testing products.  See full letter here.




Laura Hofmann, MSN, RN – Director of Clinical and Nursing Facility Regulatory Services
c: 425-231-4804